,38 These findings, supported by both previous studies and our data from clinical cohorts and in vitro experiments, suggest that dysregulation of the RB1/E2F1 axis in advanced prostate cancer may drive lethal disease progression by regulating CDRs. Here, E2F1 is linked to prostate carcinoma.